Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab. It will also assess the antitumor efficacy and pharmacokinetics of the combination therapy compared to Lutetium (177Lu) DGUL monotherapy. Participants will: Monotherapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals Combination therapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals along with pembrolizumab up to 18 times at 6-week intervals

Trial Details

NCT ID
NCT07244393
Phase
PHASE1
Sponsor
Cellbion Co., Ltd.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Lutetium (177Lu) DGUL
  • Pembrolizumab
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Male patients aged 19 years or older.
  • Patients with histopathologically or cytologically confirmed adenocarcinoma of the prostate, without neuroendocrine or small cell differentiation, …
  • Patients with serum testosterone levels meeting castration levels (\< 50 ng/dL) at the screening visit.
  • Patients must have experienced disease progression following treatment for mCRPC with a second-generation androgen receptor signaling inhibitor the…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →